COVID19
Conditions
Keywords
inhaled nitric oxide, emergency department, emergency medicine, respiratory infection
Brief summary
The spread of novel Coronavirus (2019-nCoV) related infection (COVID-19) has led to many patient presentations in the emergency department for respiratory complaints, with many of these patients requiring ICU admission and ventilatory support. While COVID-19 patients have an increased need for supportive care, there is currently no specific treatment directed against 2019-nCoV. Nitric oxide inhalation has been used as a pulmonary vasodilator and has been found to have antiviral activity against other coronavirus strains. The primary aim of this study is to determine whether inhaled NO improves short term respiratory status, prevents future hospitalization, and improves the clinical course in patients diagnosed with COVID-19 specifically in the emergency department.
Detailed description
The spread of novel Coronavirus (2019-nCoV) related infection (COVID-19) has led to many patient presentations in the emergency department for respiratory complaints, with many of these patients requiring ICU admission and ventilatory support. While COVID-19 patients have an increased need for supportive care, there is currently no specific treatment directed against 2019-nCoV. Nitric oxide inhalation has been used as a pulmonary vasodilator and has been found to have antiviral activity against other coronavirus strains. Preliminary data support a microbicidal effect of high concentration inhaled NO. We hypothesize that high concentration inhaled NO can have a viricidal effect against SARS-Cov-2 and prevent the deterioration to a severe form of COVID-19 when administered at an early stage of the disease. Additional potential mechanisms why INO may be effective in this indication: 1)improves V/Q ratio, 2) reduces PVR and PAP, 3) Anti-thrombotic in lung. This would have potential benefit for the patients in terms of reducing the severity of the clinical course and time to recovery. An additional benefit could be for the society since a faster and a less severe clinical course could protect limited hospital resources (ED, floor, and ICU) from being overwhelmed. The primary aim is to prevent the deterioration of mild COVID-19 infection (defined by a RT-PCR positive for SARS-CoV-2 in a specimen from any site) with respiratory signs/ symptoms to a more severe form of the disease as defined by the patient needing to 1) return to the ED, 2) be admitting to the hospital, 3) be intubated, 4) and all cause 28 day mortality.
Interventions
DRUGNitric Oxide Gas
Inhaled NO administered at target inspired concentration 140 - 300 ppm for 20-30 minutes
OTHERInhaled Supplemental Oxygen
2 L/min oxygen therapy
Sponsors
Massachusetts General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old * Presentation to the ED with respiratory symptoms likely caused by COVID-19 * Patient displays at least one of the following 1. respiratory rate ≥ 24 2. new cough 3. new atypical chest pain 4. new dyspnea 5. oxygen saturation \< 97% at rest 6. chest x-ray with new changes consistent with COVID-related airspace disease * Cleared for discharge home by attending physician * Obtained COVID testing (results not required at time of enrollment) * Onset of symptoms ≤12 days prior to ED visit
Exclusion criteria
* Attending physician estimation (\< 50% likelihood) of other more likely non-COVID etiology * Presence of tracheostomy * Requirement of oxygen therapy to maintain resting oxygen saturation of \> 94% * Clinical contraindication to use of inhaled nitric oxide
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rates of return visits to the ED | 28 days | Difference within treatment and control groups with COVID-related symptoms/disease in their likelihood to return to the ED with worsening symptoms |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Inpatient hospitalizations required | 28 days | Difference within treatment and control groups with COVID-related symptoms/disease in their likelihood to require hospitalization during their COVID-19 course |
| Rates of intubation | 28 days | Difference within treatment and control groups with COVID-related symptoms/disease in their likelihood to require intubation during their COVID-19 course |
| Rates of mortality | 28 days | Difference within treatment and control groups with COVID-related symptoms/disease in their likelihood to die of any cause within 28 days of their initial ED visit |
Countries
United States
Outcome results
None listed